Russell Frank Company’s Ultragenyx Pharmaceutical RARE Stock Holding History

Russell Frank Company’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$982K	Buy	15,509 +1,986	+15%	+$130K	﹤0.01%	2187
2015 Q4	$1.53M	Buy	13,523 +10,951	+426%	+$1.09M	﹤0.01%	1993
2015 Q3	$248K	Sell	2,572 -2,132	-45%	-$244K	﹤0.01%	2658
2015 Q2	$482K	Buy	+4,704	New	+$365K	﹤0.01%	2589
2014 Q4	–	Sell	-17,061	Closed	-$966K	–	3018
2014 Q3	$966K	Buy	+17,061	New	+$858K	﹤0.01%	2075

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Russell Frank Company's RARE Position: Q1 2016 in Review

Russell Frank Company increased its Ultragenyx Pharmaceutical (RARE) stake by 15% in Q1 2016, buying an estimated $130K and bringing the position to 15,509 shares worth $982K. The position accounts for ﹤0.01% of the portfolio, ranked #2187.

Russell Frank Company first reported a position in RARE in Q3 2014 and has held it in 5 quarters since. The position peaked at $1.53M in Q4 2015. 161 funds tracked by Wall St. Rank hold RARE as of Q1 2016.

Russell Frank Company held 15,509 shares of Ultragenyx Pharmaceutical worth $982K as of Q1 2016.
Russell Frank Company bought 1,986 Ultragenyx Pharmaceutical shares in Q1 2016, an estimated $130K.
Ultragenyx Pharmaceutical made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #2187 holding.
Russell Frank Company first reported a position in Ultragenyx Pharmaceutical in Q3 2014 and has held it in 5 quarters since.
Russell Frank Company's Ultragenyx Pharmaceutical position peaked at $1.53M in Q4 2015.
161 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.